Pancreatic Cancer Research

ResearcherUniversity of California, IrvineActive in the last 2 years

Mohammed Aldakkak

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-2855-3278; OpenAlex author ID A5061925957, A5075239977, A5138792067. Sources: OpenAlex.

Their work

Papers
33 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
100
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 6 papers · 2021: 5 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 6 papers

Papers 33

  1. AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1001/jamasurg.2026.0291↗
  2. Limitations of GATA6 and CK5 as surrogate markers for molecular subtyping in pancreatic cancer. First author DOI 10.1016/j.hpb.2026.08.001↗
  3. Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.jcmgh.2026.101872↗
  4. MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. Co-author DOI 10.1093/oncolo/oyag040↗
  5. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  6. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-1181↗
  7. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Co-author DOI 10.1016/j.prro.2024.07.001↗
  8. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03167-2↗
  9. The impact of socioeconomic factors on pancreatic cancer care utilization. Co-author DOI 10.1371/journal.pone.0320518↗
  10. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  11. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. First author DOI 10.1002/jso.27265↗
  12. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005884↗
  13. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13055-1↗
  14. CXCR4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0264763↗
  15. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Co-author DOI 10.1016/j.amjsurg.2020.12.001↗
  16. Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes. First author DOI 10.1038/s41698-021-00161-8↗
  17. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Co-author DOI 10.1158/1078-0432.ccr-20-2475↗
  18. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09149-3↗
  19. Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level. Co-author DOI 10.3389/fonc.2021.606820↗
  20. Black raspberries suppress pancreatic cancer through modulation of NKp46+, CD8+, and CD11b+ immune cells. Co-author DOI 10.1002/fft2.1↗
  21. Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.anndiagpath.2020.151485↗
  22. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… First author DOI 10.1016/j.surg.2020.04.031↗
  23. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003049↗
  24. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00460↗
  25. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. First author DOI 10.3389/fonc.2020.00500↗
  26. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  27. A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Meta… Co-author DOI 10.1158/1055-9965.epi-18-0813↗
  28. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07906-7↗
  29. Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. First author DOI 10.1007/s00261-017-1404-0↗
  30. Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1007/s11605-016-3319-4↗
  31. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Co-author DOI 10.1007/s11605-017-3544-5↗
  32. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? Co-author DOI 10.1016/j.prro.2017.06.013↗
  33. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. Co-author DOI 10.1111/hpb.12448↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susan Tsai · 28 shared papers, 2015–2026 · strength 3.51
  2. Douglas B. Evans · 25 shared papers, 2015–2026 · strength 3.25
  3. Kathleen K. Christians · 21 shared papers, 2015–2026 · strength 2.54
  4. William Adrian Hall · 16 shared papers, 2017–2026 · strength 2.14
  5. Mandana Kamgar · 11 shared papers, 2020–2026 · strength 1.98
  6. Callisia Nathelee Clarke · 13 shared papers, 2017–2026 · strength 1.72
  7. Bradley A. Erickson · 16 shared papers, 2015–2024 · strength 1.70
  8. Ben George · 15 shared papers, 2015–2024 · strength 1.64
  9. Sam Z. Thalji · 6 shared papers, 2023–2026 · strength 1.18
  10. Kulwinder S. Dua · 7 shared papers, 2019–2025 · strength 0.89
  11. Nikki K. Lytle · 4 shared papers, 2026 · strength 0.86
  12. Paul S. Ritch · 9 shared papers, 2015–2020 · strength 0.71
  13. Naveen M. Kulkarni · 6 shared papers, 2018–2023 · strength 0.68
  14. Thomas B. McFall · 3 shared papers, 2026 · strength 0.68
  15. Razelle Kurzrock MD · 3 shared papers, 2026 · strength 0.68
  16. Beth E. Erickson · 3 shared papers, 2025–2026 · strength 0.64
  17. Chad A. Barnes · 6 shared papers, 2017–2020 · strength 0.53
  18. Saryn Doucette · 2 shared papers, 2023–2026 · strength 0.45
  19. Parag P. Tolat · 4 shared papers, 2018–2023 · strength 0.43
  20. Ben George · 2 shared papers, 2025–2026 · strength 0.41
  21. Yongwoo David Seo · 2 shared papers, 2026 · strength 0.41
  22. Daniel Dorbin · 2 shared papers, 2026 · strength 0.41
  23. G. Aaron Hobbs · 2 shared papers, 2026 · strength 0.41
  24. Ashley N. Krepline · 5 shared papers, 2015–2021 · strength 0.40
  25. Daniel L. Adams · 2 shared papers, 2021–2022 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.